乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究

doi:10.11904/j.issn.1002-3070.2019.02.003

Abstract

Abstract: Objective The objective of this study was to investigate the relationship between CYP2D6 gene polymorphisms and the concentrations of tamoxifen metabolites in breast cancer patients. Methods Peripheral blood samples from breast cancer patients were collected to detect the single nucleotide polymorphism(SNP)of s16947,rs1065852 and rs28371725 gene sites on CYP2D6 gene from January 2010 to December 2012.Genotypes of the three SNPs of CYP2D6 and the concentrations of tamoxifen metabolites were detected in breast cancer patients.Statistical analysis was performed using an independent sample Kruskal-Wallis test in a nonparametric test. Results There was a statistical difference in the concentrations of tamoxifen metabolites 4-OH-N-D-TAM and 4'OH-N-D-TAM in the blood in different CYP2D6 gene genotype carriers at rs16947 site(P=0.049),indicating that the rs16947 site of CYP2D6 gene affected the metabolism of tamoxifen drug in breast cancer patients. Conclusion The genotype of CYP2D6 gene at rs16947 site is related to the blood concentration of tamoxifen metabolites in breast cancer patients.

Key words: Breast cancer, CYP2D6, SNP, Tamoxifen, Metabolism

CLC Number:

R737.9

CHEN Yanbo, KONG Dejia, ZHANG Jinfeng, MA Zhigang. Correlation between CYP2D6 gene polymorphism and tamoxifen metabolism in breast cancer patients[J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 110-114.

References

1 Siegel RL,Miller KD,Jemal A.Cancer statistics[J].CA Cancer J Clin,2018,68(1):7-30.
2 Hinohara K,Wu HJ,Vigneau S,et al.KDM5 Histone demethylase activity links cellular transcriptomic heterogeneity to therapeutic resistance[J].Cancer Cell,2018,34(6):939-953.
3 Early Breast Cancer Trialists' Collaborative G,Davies C,Godwin J,et al.Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen:patient-level meta-analysis of randomised trials[J].Lancet,2011,378(9793):771-784.
4 Early Breast Cancer Trialists' Collaborative G.Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomised trials[J].Lancet,2005,365(9472):1687-1717.
5 Gao A,Sun T,Ma G,et al.LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERalpha pathway[J].Nat Commun,2018,9(1):4180.
6 Lim YC,Li L,Desta Z,et al.Endoxifen,a secondary metabolite of tamoxifen,and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells[J].J Pharmacol Exp Ther,2006,318(2):503-512.
7 Lien EA,Solheim E,Kvinnsland S,et al.Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile[J].Cancer Research,1988,48(8):2304-2308.
8 Ingle JN,Suman VJ,Johnson PA,et al.Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer[J].Clin Cancer Res,1999,5(7):1642-1649.
9 Broly F,Gaedigk A,Heim M,et al.Debrisoquine/sparteine hydroxylation genotype and phenotype:analysis of common mutations and alleles of CYP2D6 in a European population[J].DNA Cell Biol,1991,10(8):545-558.
10 Madlensky L,Natarajan L,Tchu S,et al.Tamoxifen metabolite concentrations,CYP2D6 genotype,and breast cancer outcomes[J].Clin Pharmacol Ther,2011,89(5):718-725.
11 Chin FW,Chan SC,Abdul Rahman S,et al.CYP2D6 genetic polymorphisms and phenotypes in different ethnicities of malaysian breast cancer patients[J].Breast J,2016,22(1):54-62.
12 Gaedigk A,Simon SD,Pearce RE,et al.The CYP2D6 activity score:translating genotype information into a qualitative measure of phenotype[J].Clin Pharmacol Ther,2008,83(2):234-242.
13 Nowell SA,Ahn J,Rae JM,et al.Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients[J].Breast Cancer Res Treat,2005,91(3):249-258.
14 Lim HS,Ju Lee H,Seok Lee K,et al.Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer[J].J Clin Oncol,2007,25(25):3837-3845.
15 Jin Y,Desta Z,Stearns V,et al.CYP2D6 genotype,antidepressant use,and tamoxifen metabolism during adjuvant breast cancer treatment[J].J Natl Cancer Inst,2005,97(1):30-39.
16 Xu Y,Sun Y,Yao L,et al.Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment[J].Ann Oncol,2008,19(8):1423-1429.
17 Okishiro M,Taguchi T,Jin Kim S,et al.Genetic polymorphisms of CYP2D6 10 and CYP2C19 2,3 are not associated with prognosis,endometrial thickness,or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen[J].Cancer,2009,115(5):952-961.
18 Rae JM,Drury S,Hayes DF,et al.CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients[J].J Natl Cancer Inst,2012,104(6):452-460.
19 Jung JA,Lim HS.Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer:a meta-analysis[J].Pharmacogenomics,2014,15(1):49-60.

[1]	WANG Xiaoya,XIAO Bin,LIAO Yang,TANG Rongzhi,SUN Zhaohui,LI Linhai. Expression of CXCR family proteins in different subtypes of breast cancer and their clinical prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 206-210.
[2]	LI Shuo,ZHANG Nannan,LI Liangliang,LONG Zhiping,YIN Huihui,ZHAO Yashuang,WANG Fan. Relationship between PDE4C gene methylation in peripheral blood leukocytes,interaction of environmental factors and pathogenesis of breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 233-238.
[3]	SUN Jianghong, HAO Mingzhu, JIANG Dan, GUO Fei, LI Xiaomei. FFDM differential diagnosis of mastitis,benign hyperplasia and breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 139-141.
[4]	MA Zhijie, WANG Fan, ZHAO Yashuang. Analysis of life quality and influencing factors in breast cancer patients with chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 149-154.
[5]	TONG Guanghai, TIAN Yang, WU Huaxing. Application of lipidomics in colorectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 179-192.
[6]	MA Zhingying, SHANG Naijian, CAI Miaotian, SHEN Yang, JIANG Zhiyun. Correlation between HER-2 receptor of progesterone and estrogen receptor-positive breast cancer and mammography imaging & clinicopathological features [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 47-51.
[7]	HE Xu, YE shangmian, DONG dandan, LI Ke. The expression of HLA-G in breast cancer and its significance [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 410-414.
[8]	ZHANG Yiyun,WU Huaxing. Progress of metabolic plasticity in tumor growth and metastasis [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 362-366.
[9]	LIN Rongjie, YIN Hang, ZHOU Yunfeng. Effect of ON123300 on ER+ human breast cancer MCF-7 cells and its mechanism [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 193-197.
[10]	LI Lin, LI Zhigao. The relationship between metformin and different molecular subtypes of breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 267-270.
[11]	ZHENG Wei, XU Shouping, PANG Da. Expression,prognosis and function of long chain non-coding RNA-Linc00152 in breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 7-13.
[12]	YIN Yulian, ZHANG Weihong, ZHOU Yue, YE Meina, CHEN Hongfeng. Correlation between single nucleotide polymorphisms of ERα gene and bone loss associated with aromatase inhibitors in postmenopausal women with breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 14-18.
[13]	LI Yujiao, SHANG Naijian. Research progress of imaging evaluation of neoadjuvant chemotherapy in breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 63-67.
[14]	WANG Xiaoxiao, HUA Teng, WANG Hongbo. Research progress of estrogen receptor-related receptor γ in tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 87-91.
[15]	CHEN Zhuo, KONG Yiran. Effect of silencing UHRF1 on proliferation and metastasis of breast cancer cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 512-518.

Correlation between CYP2D6 gene polymorphism and tamoxifen metabolism in breast cancer patients

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments